Upper-extremity impairment after stroke remains a major therapeutic challenge and a target of neuromodulation treatment efforts.In this open-label, randomized phase I trial, we applied deep brain stimulation to the cerebellar dentate nucleus combined with bilateral or unilateral stimulation. Vagus nerve stimulation was also conducted for motor function after ischaemic Stroke.We hypothesized that cerebellar stimulation was superior to vagus stimulation as the motor rehabilitation after stroke benefits from both side of cerebellum.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
100
Participants underwent stereotactic implantation of a single DBS lead in the area of the cerebellar DN contralateral to the lesioned cerebral hemisphere using a frame-based technique similar to that used in DBS for movement disorders. All participants received an 4-channel lead (Medtronic,3389)with electrode arrays up to 15.5 mm in length. Then bilateral stimulation was activated after 1 month post-DBS
Participants underwent stereotactic implantation of a single DBS lead in the area of the cerebellar DN contralateral to the lesioned cerebral hemisphere using a frame-based technique similar to that used in DBS for movement disorders. All participants received an 4-channel lead (Medtronic,3389)with electrode arrays up to 15.5 mm in length. Then unilateral stimulation was activated after 1 month post-DBS
Device implantation was done under general anaesthesia. A horizontal neck crease incision was created left of the midline at the level of the cricoid cartilage. After the vagus nerve was identified, the stimulation lead was wrapped around the vagus nerve. The lead was then tunnelled subcutaneously to the pulse generator device which was contained in a subcutaneous pocket in the pectoral region.
Chao Zhang
Jinan, Shandong, China
RECRUITINGFM-UE scores between cerebellar DBS and VNS
The outcomes includes each participant's Fugl-Meyer assessment scale (FM-UE) scores for each monthly visit. FM-UE scores range from 0 to 100 and the higher scores indicated better outcome of movement.
Time frame: 12 months after device implantation
Arm Motor Ability Test (AMAT) between cerebellar DBS and VNS
The outcomes includes each participant's the Arm Motor Ability Test (AMAT) for each monthly visit. AMAT scores range from 0 to 57 and the higher scores indicated better outcome of movement.
Time frame: 12 months after device implantation
the Nine-Hole Peg Test between cerebellar DBS and VNS
The outcomes includes each participant's the Nine-Hole Peg Test for each monthly visit.
Time frame: 12 months after device implantation
the Bilateral Box and Block Test between cerebellar DBS and VNS
The outcomes includes each participant's the Bilateral Box and Block Test for each monthly visit.
Time frame: 12 months after device implantation
Short Form Health Survey (SF-12) between cerebellar DBS and VNS
The outcomes includes each participant's score of Short Form Health Survey (SF-12) for each monthly visit. SF-12 scores range from 0 to 60 and the higher scores indicated better outcome of movement.
Time frame: 12 months after device implantation
the EuroQol Five Dimensions Questionnaire (EQ-5D) between cerebellar DBS and VNS
The outcomes includes each participant's score of the EuroQol (EQ-5D) scores range from 0 to 36 for each monthly visit.
Time frame: 12 months after device implantation
the Beck Depression Inventory or the Beck Anxiety Inventory between cerebellar DBS and VNS
The outcomes includes each participant's score of the Beck Depression Inventory or the Beck Anxiety Inventory for each monthly visit.
Time frame: 12 months after device implantation
nerve conduction velocity between cerebellar DBS and VNS
The outcomes includes each participant's nerve conduction velocity for each monthly visit recorded by flexible electrode.
Time frame: 12 months after device implantation
safety and feasibility of VNS and cerebellar DBS
The incidence of adverse events including hemorrhages, infections, deaths or major perioperative complications during the study
Time frame: 12 months after device implantation
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.